Routine board appointment with no immediate trading implications. Monitor for any future strategic shifts, but this filing alone does not warrant action.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 8 $73.80entry
- T+1 · 4mo ago +3.74%α +2.89% · $76.56
- T+5 · 4mo ago −8.62%α −9.48% · $67.44
- T+20 · 3mo ago −23.77%α −27.05% · $56.26
- T+60 · 7w ago +160.94%α +158.62% · $192.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Moderna appointed Michael McDonnell, former CFO of Biogen, to its Board of Directors effective July 8, 2026. McDonnell will also serve on the Audit Committee. This is a routine board governance change with no material financial or operational impact.
Key Facts
- Michael McDonnell appointed to Board of Directors effective July 8, 2026
- McDonnell formerly served as CFO of Biogen Inc. (Aug 2020, Feb 2025) and previously at IQVIA, Intelsat, MCG Capital, and EchoStar
- McDonnell will serve as Class II director until the 2029 annual meeting and on the Audit Committee
- David Rubenstein moved off the Audit Committee to the Nominating and Corporate Governance Committee
Financial Impact
No financial impact from this board appointment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001682852-26-000134 |
| Exhibit: exhibit991-07082026.htm | 0001682852-26-000134 |
| Document: 0001682852-26-000134-index-headers.html | 0001682852-26-000134 |
| Document: 0001682852-26-000134-index.html | 0001682852-26-000134 |
| Document: 0001682852-26-000134.txt | 0001682852-26-000134 |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers